Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10931506,steady-state plasma concentrations,"Maternal steady-state plasma concentrations of d4T were 1-2 microg/ml, with a fetal-to-maternal plasma ratio of 0.85 +/- 0.09.","Transplacental pharmacokinetics and fetal distribution of 2', 3'-didehydro-3'-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10931506/),[μg] / [ml],1-2,425,DB01159,Halothane
,10931506,plasma ratio,"Maternal steady-state plasma concentrations of d4T were 1-2 microg/ml, with a fetal-to-maternal plasma ratio of 0.85 +/- 0.09.","Transplacental pharmacokinetics and fetal distribution of 2', 3'-didehydro-3'-deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10931506/),,0,426,DB01159,Halothane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.35,2177,DB01159,Halothane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.45,2178,DB01159,Halothane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,0.94,2179,DB01159,Halothane
,2400116,blood/gas partition coefficient,"The blood/gas partition coefficient of desflurane (0.35 +/- 0.02) was significantly smaller (P less than 0.01) than that of sevoflurane (0.45 +/- 0.02), isoflurane (0.94 +/- 0.05), and halothane (2.54 +/- 0.21).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),,2.54,2180,DB01159,Halothane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,93,2181,DB01159,Halothane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,77,2182,DB01159,Halothane
,2400116,Recovery,"Recovery (normalized to that of isoflurane) of the volume of anesthetic taken up was significantly greater (P less than 0.05) for desflurane (93% +/- 7% [mean +/- SD]) than for halothane (77% +/- 6%), was not different from that of isoflurane (100%), but was less than that for sevoflurane (111% +/- 17%).","Pharmacokinetics of desflurane, sevoflurane, isoflurane, and halothane in pigs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400116/),%,111,2183,DB01159,Halothane
,3425871,Elimination half-life,Elimination half-life ranged from 0.72 to 15.06 h.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,0.72 to 15.06,3654,DB01159,Halothane
,3425871,Cl,Cl ranged from 2.5 to 12.8 ml/min per kilogram.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),[ml] / [kg·min],2.5 to 12.8,3655,DB01159,Halothane
,3425871,t1/2el,Four patients (= 9%) had a t1/2el of 7-15 h; in 16 cases we found secondary concentration peaks.,[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,7-15,3656,DB01159,Halothane
up to,3425871,half-life,"In accordance with others, we found some patients with a half-life of up to 15 h, which might reflect the influence of the anesthesia itself.",[The pharmacokinetics of midazolam in various kinds of anesthesia]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3425871/),h,15,3657,DB01159,Halothane
,2917110,elimination half-life,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,207,3761,DB01159,Halothane
,2917110,elimination half-life,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,153,3762,DB01159,Halothane
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),l,147,3763,DB01159,Halothane
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),l,128,3764,DB01159,Halothane
,2917110,volume of distribution at steady state,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],587,3765,DB01159,Halothane
,2917110,clearance,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],587,3766,DB01159,Halothane
,2917110,clearance,"There were no differences between groups with respect to the elimination half-life (awake group: 207 min; anaesthetized group: 153 min), volume of distribution at steady state (awake: 147 litre; anaesthetized: 128 litre), or clearance (awake: 587 ml min-1; anaesthetized: 766 ml min-1).",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),[ml] / [min],766,3767,DB01159,Halothane
,2917110,AUC,"The AUC for M3G and M6G (0-180 min) also were greater in the anaesthetized patients, presumably as a result of decreases in renal blood flow and glomerular filtration rate during halothane anaesthesia.",Studies on morphine disposition: influence of general anaesthesia on plasma concentrations of morphine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2917110/),min,0,3768,DB01159,Halothane
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],496,8051,DB01159,Halothane
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],2104,8052,DB01159,Halothane
,8881626,plasma concentrations,"Mean plasma concentrations of ketamine peaked at 496 ng ml-1 in group IN3 within 20 min, 2104 ng ml-1 in group IN9 within 21 min, and 632 ng ml-1 in group IR9 within 42 min.","Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),[ng] / [ml],632,8053,DB01159,Halothane
,8881626,bioavailability,Calculated bioavailability was 0.50 in groups IN3 and IN9 and 0.25 in group IR9.,"Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),,0.50,8054,DB01159,Halothane
,8881626,bioavailability,Calculated bioavailability was 0.50 in groups IN3 and IN9 and 0.25 in group IR9.,"Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881626/),,0.25,8055,DB01159,Halothane
,495919,half-life (t0.5),Rats exposed to halothane (100 ppm) in a closed allglass-system eliminate halothane from the atmosphere of this system with a half-life (t0.5) of 0.99 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.99,8118,DB01159,Halothane
,495919,t0.5,In 24 h-fasted rats t0.5 was prolonged to 1.24 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.24,8119,DB01159,Halothane
,495919,t0.5,"On the other hand, ethanol (4.8 g/kg p.o.) applied 5 min before exposure to halothane markedly prolonged t0.5 to 3.79 h.","[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,3.79,8120,DB01159,Halothane
,495919,t0.5,Pretreatment with phenobarbital (80 mg/kg i.p. for 4 days) shortened t0.5 significantly to 0.79 h.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,0.79,8121,DB01159,Halothane
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,7.53,8122,DB01159,Halothane
,495919,t0.5,Inhibition of the mixed-function oxidase system by dithiocarb (100 mg/kg i.p.) or diethyl maleate (1 ml/kg i.p.) markedly prolonged t0.5 to 7.53 and 1.57 h. respectively.,"[The influence of ethanol, dithiocarb, diethylmaleate and phenobarbital on the metabolic elimination of halothane in rats (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/495919/),h,1.57,8123,DB01159,Halothane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8706,DB01159,Halothane
,8678276,Peak serum IFCs,Peak serum IFCs were higher with sevoflurane (34.5 mumol/l) than with enflurane (19.4 mumol/l).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],19.4,8707,DB01159,Halothane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],688,8708,DB01159,Halothane
,8678276,area under the curve (AUC),The area under the curve (AUC) was greater with sevoflurane (688 mumol/l.h) than with enflurane (591 mumol/l.h).,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [h·l],591,8709,DB01159,Halothane
,8678276,peak serum IFCs,In our study 1.69 MAC-h sevoflurane produced peak serum IFCs of 34.5 mumol/l.,"[Serum fluoride concentrations and exocrine kidney function with sevoflurane and enflurane. An open, randomized, comparative phase III study of patients with healthy kidneys]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8678276/),[μM] / [l],34.5,8710,DB01159,Halothane
,31898152,peak plasma concentrations,"Poyendarone hydrochloride in doses of 0.3 and 3 mg/kg over 30 s was intravenously administered to the halothane-anesthetized dogs (n = 4), which provided peak plasma concentrations of 108 ± 10 and 1120 ± 285 ng/mL, respectively.","How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898152/),[ng] / [ml],108,13998,DB01159,Halothane
,31898152,peak plasma concentrations,"Poyendarone hydrochloride in doses of 0.3 and 3 mg/kg over 30 s was intravenously administered to the halothane-anesthetized dogs (n = 4), which provided peak plasma concentrations of 108 ± 10 and 1120 ± 285 ng/mL, respectively.","How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31898152/),[ng] / [ml],1120,13999,DB01159,Halothane
,7741284,weight-normalized plasma clearance,"With mixed-effects modeling, weight-normalized plasma clearance varied with weight (P < 0.01), being 79.4 ml.min-1 + 3.13 ml.kg-1.min-1.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [min],79.4,18862,DB01159,Halothane
,7741284,weight-normalized distributional clearance,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg·min],2.67,18863,DB01159,Halothane
,7741284,weight-normalized central compartment volume,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg],106,18864,DB01159,Halothane
,7741284,weight-normalized volume of distribution at steady-state,"Neither weight-normalized distributional clearance (2.67 ml.kg-1.min-1), weight-normalized central compartment volume (106 ml/kg), nor weight-normalized volume of distribution at steady-state (224 ml/kg) varied with weight, height, or age.",Pharmacokinetics of rocuronium in children aged 4-11 years. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741284/),[ml] / [kg],224,18865,DB01159,Halothane
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,176,19818,DB01159,Halothane
,2394062,terminal half-life,"Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean ( +/- SD) terminal half-life (176 +/- 84 and 516 +/- 262 minutes for patients with normal and impaired renal function, respectively).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,516,19819,DB01159,Halothane
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,27.1,19820,DB01159,Halothane
,2394062,half-life,"Moreover, the half-life of the quaternary alcohol increased from 27.1 +/- 8.3 minutes in patients with normal renal function to 42.5 +/- 8.3 minutes in those with impaired renal function (mean +/- SD).",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,42.5,19821,DB01159,Halothane
,2394062,total duration of neuromuscular blockade,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,51.8,19822,DB01159,Halothane
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,9.6,19823,DB01159,Halothane
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,64.1,19824,DB01159,Halothane
,2394062,recovery index,"The total duration of neuromuscular blockade (51.8 +/- 11.5 minutes) and the recovery index (9.6 +/- 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 +/- 7.2 and 16.7 +/- 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.",Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394062/),min,16.7,19825,DB01159,Halothane
,8230404,elimination half-life,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),min,90.9,26142,DB01159,Halothane
,8230404,elimination half-life,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),min,75.2,26143,DB01159,Halothane
,8230404,volume of distribution at steady state,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg],4889,26144,DB01159,Halothane
,8230404,volume of distribution at steady state,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg],4863,26145,DB01159,Halothane
,8230404,clearance,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg·min],58.6,26146,DB01159,Halothane
,8230404,clearance,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg·min],56.3,26147,DB01159,Halothane
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.01,26632,DB01159,Halothane
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.16,26633,DB01159,Halothane
,8048569,Late proximal (TF/P)Li,"Late proximal (TF/P)Li was 1.01 after oral Li+, 1.16 after intravenous Li+ (P < 0.01), and 1.00 during osmotic diuresis.",Active lithium transport by rat renal proximal tubule: a micropuncture study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8048569/),,1.00,26634,DB01159,Halothane
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],22.3,30592,DB01159,Halothane
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],12.8,30593,DB01159,Halothane
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],309,32109,DB01159,Halothane
,2536254,volume of distribution at steady state,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg],442,32110,DB01159,Halothane
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32111,DB01159,Halothane
,2536254,plasma clearance,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32112,DB01159,Halothane
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,140,32113,DB01159,Halothane
,2536254,mean residence time,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,329,32114,DB01159,Halothane
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,137,32115,DB01159,Halothane
,2536254,elimination half-life,"The pharmacokinetic parameters derived by compartmental modelling were (normal vs. renal failure, respectively): volume of distribution at steady state (309 +/- 103 vs. 442 +/- 158 ml.kg-1, mean +/- SD), plasma clearance, (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (140 +/- 63 vs. 329 +/- 198 min), and elimination half-life (137 +/- 68 vs. 263 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,263,32116,DB01159,Halothane
,2536254,volume of distribution at steady state,"The same parameters as derived by the non-compartmental method were (normal vs. renal failure, respectively): volume of distribution at steady state (307 +/- 80 vs.",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),,307,32117,DB01159,Halothane
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],2.4,32118,DB01159,Halothane
,2536254,plasma clearance,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),[ml] / [kg·min],1.6,32119,DB01159,Halothane
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,134,32120,DB01159,Halothane
,2536254,mean residence time,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,323,32121,DB01159,Halothane
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,118,32122,DB01159,Halothane
,2536254,elimination half-life,"426 +/- 119 ml.kg-1, mean +/- SD), plasma clearance (2.4 +/- 0.6 vs. 1.6 +/- 0.6 ml.kg-1.min-1), mean residence time (134 +/- 41 vs. 323 +/- 228 min), and elimination half-life (118 +/- 35 vs. 247 +/- 168 min).",The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536254/),min,247,32123,DB01159,Halothane
,10201688,CO,The CO of individual pigs varied from 1.33 to 6.44 l/min.,Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201688/),[l] / [min],1.33 to 6.44,35223,DB01159,Halothane
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],3.7,36689,DB01159,Halothane
,2886080,plasma clearance,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg·min],5.2,36690,DB01159,Halothane
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],179,36691,DB01159,Halothane
,2886080,volume of distribution at steady-state,"For vecuronium, plasma clearance (3.7 +/- 1.0 and 5.2 +/- 0.8 ml X kg-1 X min-1, respectively), and volume of distribution at steady-state (179 +/- 31 and 244 +/- 38 ml X kg-1, respectively) were lower in the elderly than in young adults; values for distribution half-lives, elimination half-life, and sensitivity of the neuromuscular junction were similar for the two groups.",Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886080/),[ml] / [kg],244,36692,DB01159,Halothane
,8126766,time to standing,Recovery times were rapid with a mean time to standing after halothane inhalation ceased of 13.7 min.,Propofol as an induction agent in the goat: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),min,13.7,37604,DB01159,Halothane
,8126766,elimination half-life,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),min,15.5,37605,DB01159,Halothane
,8126766,volume of distribution at steady state,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),[l] / [kg],2.56,37606,DB01159,Halothane
,8126766,clearance,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),[ml] / [kg·min],275,37607,DB01159,Halothane
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,31.5,42114,DB01159,Halothane
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,29.1,42115,DB01159,Halothane
,3418351,half-lives,"The half-lives of cocaine in the blood, nucleus accumbens, and anteromedial caudate-putamen were estimated to be 31.5, 29.1, and 21.4 min, respectively.",In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418351/),min,21.4,42116,DB01159,Halothane
,3179149,elimination half-life,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),min,127,42436,DB01159,Halothane
,3179149,Vdss,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),l,103,42437,DB01159,Halothane
,3179149,plasma clearance,"During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1.",Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3179149/),[ml] / [min],732,42438,DB01159,Halothane
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],320,42725,DB01159,Halothane
,2877596,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was greater (P less than 0.05) after vecuronium (320 +/- 181 ml/kg; mean +/- SD) than after pancuronium (203 +/- 36 ml/kg).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg],203,42726,DB01159,Halothane
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],2.8,42727,DB01159,Halothane
,2877596,Plasma clearance,Plasma clearance of vecuronium (2.8 +/- 0.9 ml X min-1 X kg-1) was greater than that of pancuronium (1.7 +/- 0.2 ml X min-1 X kg-1; P less than 0.05).,Pharmacokinetics and pharmacodynamics of vecuronium and pancuronium in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2877596/),[ml] / [kg·min],1.7,42728,DB01159,Halothane
,6132566,clearance,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],5.2,46796,DB01159,Halothane
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,71,46797,DB01159,Halothane
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),[ml] / [kg·min],1.8,46798,DB01159,Halothane
,6132566,elimination half-life,Vecuronium had a more rapid clearance (5.2 +/- 0.7 ml X kg-1 X min-1; mean +/- SD) and a shorter elimination half-life (71 +/- 20 min) as compared with pancuronium (1.8 +/- 0.4 ml X kg-1 X min-1; 140 +/- 25 min).,Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132566/),min,140,46799,DB01159,Halothane
,8880990,t1/2 beta,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),min,83.9,47554,DB01159,Halothane
,8880990,residence time,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),min,99.0,47555,DB01159,Halothane
,8880990,body clearance,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),[ml] / [kg·min],34.5,47556,DB01159,Halothane
,8880990,volume of distribution at steady state,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),[ml] / [kg],3864,47557,DB01159,Halothane
,10490070,volume of distribution,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[l] / [kg],0.18,47744,DB01159,Halothane
,10490070,half-life,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),min,34.9,47745,DB01159,Halothane
,10490070,clearance,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[ml] / [kg·min],12,47746,DB01159,Halothane
,3499160,T1/2 alpha,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,3,49295,DB01159,Halothane
,3499160,T1/2 beta,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,45,49296,DB01159,Halothane
,3499160,total body clearance,The total body clearance of propofol was rapid (1.91 litre min-1).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),[l] / [min],1.91,49297,DB01159,Halothane
,3499160,Vss,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,305,49298,DB01159,Halothane
,3499160,V gamma,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,722,49299,DB01159,Halothane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.76,52559,DB01159,Halothane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,6.84,52560,DB01159,Halothane
,7220596,elimination half-lives,"In male rats the elimination half-lives from the atmosphere of the exposure system amounted to 0.76h for halothane, 6.84h for enflurane and 0.64h for methoxyflurane.","Effects of thyroid dysfunction on the metabolism of halothane, enflurane and methoxyflurane in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7220596/),h,0.64,52561,DB01159,Halothane
,2301759,elimination half-life,The increase in Vss without an age-related increase in Cltotal resulted in a longer elimination half-life [21.8 (+)/- 3.3 vs.,Pharmacokinetics and pharmacodynamics of atracurium in the elderly. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301759/),,21.8,57845,DB01159,Halothane
,3940218,LD50,The LD50 (30 day) for cyclophosphamide without halothane was 251 mg/kg; with 2 h subsequent exposure to halothane it was 152 mg/kg; and with 20 h subsequent exposure to halothane it was 158 mg/kg.,Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),[mg] / [kg],251,60846,DB01159,Halothane
,3940218,LD50,The LD50 (30 day) for cyclophosphamide without halothane was 251 mg/kg; with 2 h subsequent exposure to halothane it was 152 mg/kg; and with 20 h subsequent exposure to halothane it was 158 mg/kg.,Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),,152,60847,DB01159,Halothane
,3940218,LD50,The LD50 (30 day) for cyclophosphamide without halothane was 251 mg/kg; with 2 h subsequent exposure to halothane it was 152 mg/kg; and with 20 h subsequent exposure to halothane it was 158 mg/kg.,Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),[mg] / [kg],158,60848,DB01159,Halothane
,3940218,survival time,"The median survival time of mice receiving cyclophosphamide at doses between 137 and 240 mg/kg was more than 30 days in the absence of halothane, 12 days with 2 h halothane, and 10.5 days with 20 h halothane exposure.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),d,more,60849,DB01159,Halothane
,3940218,survival time,"The median survival time of mice receiving cyclophosphamide at doses between 137 and 240 mg/kg was more than 30 days in the absence of halothane, 12 days with 2 h halothane, and 10.5 days with 20 h halothane exposure.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),d,30,60850,DB01159,Halothane
,3940218,survival time,"The median survival time of mice receiving cyclophosphamide at doses between 137 and 240 mg/kg was more than 30 days in the absence of halothane, 12 days with 2 h halothane, and 10.5 days with 20 h halothane exposure.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),d,12,60851,DB01159,Halothane
,3940218,survival time,"The median survival time of mice receiving cyclophosphamide at doses between 137 and 240 mg/kg was more than 30 days in the absence of halothane, 12 days with 2 h halothane, and 10.5 days with 20 h halothane exposure.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),d,10.5,60852,DB01159,Halothane
,3940218,Total-body clearance,"Total-body clearance of cyclophosphamide in mice exposed to halothane was 60 ml/min/kg, as against 188 ml/min/kg in nonexposed mice.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),[ml] / [kg·min],60,60853,DB01159,Halothane
,3940218,Total-body clearance,"Total-body clearance of cyclophosphamide in mice exposed to halothane was 60 ml/min/kg, as against 188 ml/min/kg in nonexposed mice.",Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940218/),[ml] / [kg·min],188,60854,DB01159,Halothane
,8214905,PaCO2,"Positive pressure ventilation was begun, maintaining PaCO2 at 49.1 +/- 3.3 mm of Hg and airway pressure at 20 +/- 2 cm of H2O.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),h·mm,49.1,60921,DB01159,Halothane
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],94.8,60922,DB01159,Halothane
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],170.7,60923,DB01159,Halothane
,8214905,plasma alfentanil concentration,"Mean +/- SD measured plasma alfentanil concentration during the infusions were 94.8 +/- 29.0, 170.7 +/- 29.2 and 390.9 +/- 107.4 ng/ml.",Evaluation of the effect of alfentanil on the minimum alveolar concentration of halothane in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8214905/),[ng] / [ml],390.9,60924,DB01159,Halothane
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],42.3,66366,DB01159,Halothane
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],12.3,66367,DB01159,Halothane
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],3.19,66368,DB01159,Halothane
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],0.99,66369,DB01159,Halothane
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.85,66370,DB01159,Halothane
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.46,66371,DB01159,Halothane
,8198908,Recovery,Recovery was slowest with the propofol infusion (mean 39.8 (SD 12.9) min when eyes opened on command).,"Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,39.8,72637,DB01159,Halothane
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,21.9,72638,DB01159,Halothane
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,23.4,72639,DB01159,Halothane
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,20.1,72640,DB01159,Halothane
,3257879,clearance,The clearance of propofol was significantly lower in the elderly (1.44 +/- 0.10 (SE) litre min-1) than in the younger patients (1.79 +/- 0.12 litre min-1).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),[l] / [min],1.44,77947,DB01159,Halothane
,3257879,clearance,The clearance of propofol was significantly lower in the elderly (1.44 +/- 0.10 (SE) litre min-1) than in the younger patients (1.79 +/- 0.12 litre min-1).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),[l] / [min],1.79,77948,DB01159,Halothane
,3257879,volume of the central compartment,The volume of the central compartment in the elderly patients was significantly smaller (19.6 +/- 5.2 litre) than that in the young (26.3 +/- 2.9 litre).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,19.6,77949,DB01159,Halothane
,3257879,volume of the central compartment,The volume of the central compartment in the elderly patients was significantly smaller (19.6 +/- 5.2 litre) than that in the young (26.3 +/- 2.9 litre).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,26.3,77950,DB01159,Halothane
,3257879,volume of distribution at equilibrium,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,1608,77951,DB01159,Halothane
,3257879,volume of distribution at equilibrium,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,1757,77952,DB01159,Halothane
,3257879,volume of distribution at steady state,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,691,77953,DB01159,Halothane
,3257879,volume of distribution at steady state,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,771,77954,DB01159,Halothane
,2889555,steady-state volume,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.21,79728,DB01159,Halothane
,2889555,clearance,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],2.9,79729,DB01159,Halothane
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,100,79730,DB01159,Halothane
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[l] / [kg],0.20,79731,DB01159,Halothane
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[ml] / [kg·min],3.2,79732,DB01159,Halothane
,2889555,elimination half-life,"For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively.",Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),min,84,79733,DB01159,Halothane
,2889555,Plasma concentrations,Plasma concentrations associated with 50% blockade averaged 0.2 microgram/ml for both groups.,Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2889555/),[μg] / [ml],0.2,79734,DB01159,Halothane
,9989340,blood/gas partition coefficient,The more rapid pharmacokinetics are a result of the low blood/gas partition coefficient of 0.69.,Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,0.69,82479,DB01159,Halothane
,9989340,oil/gas partition coefficient,"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),,47.2,82480,DB01159,Halothane
,9989340,minimum alveolar concentration (MAC),"With an oil/gas partition coefficient of 47.2, the minimum alveolar concentration (MAC) of sevoflurane is 2.05%.",Clinical pharmacokinetics of sevoflurane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9989340/),%,2.05,82481,DB01159,Halothane
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],88,88198,DB01159,Halothane
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],116,88199,DB01159,Halothane
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],130,88200,DB01159,Halothane
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.13,88201,DB01159,Halothane
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.48,88202,DB01159,Halothane
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.74,97583,DB01159,Halothane
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.52,97584,DB01159,Halothane
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.41,97585,DB01159,Halothane
,7114542,steady-state distribution volume (Vdss),"The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),[l] / [kg],0.30,97586,DB01159,Halothane
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,174,97587,DB01159,Halothane
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,90,97588,DB01159,Halothane
,7114542,elimination half-life (t beta 1/2),"The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively.","Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7114542/),min,89,97589,DB01159,Halothane
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],182,97918,DB01159,Halothane
,8329252,Cmax,"After nasal and rectal administration, midazolam Cmax was 182 (SD 57) ng ml-1 within 12.6 (5.9) min, and 48 (16) ng ml-1 within 12.1 (6.4) min, respectively.","Plasma concentrations of midazolam after i.v., nasal or rectal administration in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8329252/),[ng] / [ml],48,97919,DB01159,Halothane
,12027844,onset time,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,1.4,107643,DB01159,Halothane
,12027844,onset time,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,1.3,107644,DB01159,Halothane
,12027844,time to first response,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,9.6,107645,DB01159,Halothane
,12027844,time to first response,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,10.5,107646,DB01159,Halothane
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],5.5,107647,DB01159,Halothane
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],51.0,107648,DB01159,Halothane
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],30.5,107649,DB01159,Halothane
,1744940,elimination half-life (t1/2 beta),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,21.65,110196,DB01159,Halothane
,1744940,clearance (Cl),The elimination half-life (t1/2 beta) was 21.65 +/- 3.99 min and the clearance (Cl) was 14.1 +/- 0.7 ml/kg/min.,The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14.1,110197,DB01159,Halothane
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,55.95,110198,DB01159,Halothane
,1744940,t1/2 beta,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),min,68.03,110199,DB01159,Halothane
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],14,110200,DB01159,Halothane
,1744940,Cl,"The t1/2 beta for alfentanil under halothane and isoflurane anaesthesia were 55.95 +/- 20.77 and 68.03 +/- 23.22 min, respectively, and the Cl values were 14 +/- 1.7 and 13.6 +/- 1.32 ml/kg/min.",The pharmacokinetics and locomotor activity of alfentanil in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1744940/),[ml] / [kg·min],13.6,110201,DB01159,Halothane
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,75,111543,DB01159,Halothane
,1348166,Times to 50% recovery of twitch,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,46,111544,DB01159,Halothane
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,14.9,111545,DB01159,Halothane
,1348166,5%-25% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,10.0,111546,DB01159,Halothane
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,38.4,111547,DB01159,Halothane
,1348166,25%-75% recovery times,Times to 50% recovery of twitch were longer in the obese than in the control patients (75 +/- 8 versus 46 +/- 8 min) as were 5%-25% recovery times (14.9 +/- 4.0 versus 10.0 +/- 1.7 min) and 25%-75% recovery times (38.4 +/- 13.8 versus 16.7 +/- 10.3 min).,Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,16.7,111548,DB01159,Halothane
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],791,111549,DB01159,Halothane
,1348166,total volume of distribution,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[ml] / [kg],919,111550,DB01159,Halothane
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],4.65,111551,DB01159,Halothane
,1348166,plasma clearance,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),[kg·ml] / [ibw·min],5.02,111552,DB01159,Halothane
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,119,111553,DB01159,Halothane
,1348166,elimination half-life,"When the data were calculated on the basis of ideal body weight (IBW) for obese and control patients, total volume of distribution (791 +/- 303 versus 919 +/- 360 mL/kg IBW), plasma clearance (4.65 +/- 0.89 versus 5.02 +/- 1.13 mL.min-1.kg IBW-1), and elimination half-life (119 +/- 43 versus 133 +/- 57 min) were not different between groups.",Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1348166/),min,133,111554,DB01159,Halothane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.99,113473,DB01159,Halothane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.90,113474,DB01159,Halothane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.73,113475,DB01159,Halothane
,2001028,FA/FI,"FA/FI values at 30 min of administration were: (mean +/- SD) nitrous oxide 0.99 +/- 0.01, desflurane 0.90 +/- 0.01, isoflurane 0.73 +/- 0.03, and halothane 0.58 +/- 0.04.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.58,113476,DB01159,Halothane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.14,113477,DB01159,Halothane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.22,113478,DB01159,Halothane
,2001028,FA/FA0,"FA/FA0 values after 5 min of elimination were: desflurane 0.14 +/- 0.02, isoflurane 0.22 +/- 0.02, and halothane 0.25 +/- 0.02.","Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),,0.25,113479,DB01159,Halothane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,105,113480,DB01159,Halothane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,102,113481,DB01159,Halothane
,2001028,Recovery,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,64,113482,DB01159,Halothane
,2001028,volume of,Recovery (volume of anesthetic recovered during elimination per volume taken up) of desflurane (105 +/- 25%) equalled recovery of isoflurane (102 +/- 13%) and exceeded recovery of halothane (64 +/- 9%).,"Kinetics of desflurane, isoflurane, and halothane in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2001028/),%,105,113483,DB01159,Halothane
,8498660,elimination half-life,"The pharmacokinetic parameters (mean +/- SD) for the studied population were elimination half-life: 101.5 +/- 26.4 min, mean residence time: 127.2 +/- 28.6 min, volume of distribution at steady state: 0.58 +/- 0.29 L/kg and clearance: 4.66 +/- 2.28 mL.kg-1 x min-1.",The pharmacokinetics of droperidol in anesthetized children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498660/),min,101.5,116737,DB01159,Halothane
,8498660,mean residence time,"The pharmacokinetic parameters (mean +/- SD) for the studied population were elimination half-life: 101.5 +/- 26.4 min, mean residence time: 127.2 +/- 28.6 min, volume of distribution at steady state: 0.58 +/- 0.29 L/kg and clearance: 4.66 +/- 2.28 mL.kg-1 x min-1.",The pharmacokinetics of droperidol in anesthetized children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498660/),min,127.2,116738,DB01159,Halothane
,8498660,volume of distribution at steady state,"The pharmacokinetic parameters (mean +/- SD) for the studied population were elimination half-life: 101.5 +/- 26.4 min, mean residence time: 127.2 +/- 28.6 min, volume of distribution at steady state: 0.58 +/- 0.29 L/kg and clearance: 4.66 +/- 2.28 mL.kg-1 x min-1.",The pharmacokinetics of droperidol in anesthetized children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498660/),[l] / [kg],0.58,116739,DB01159,Halothane
,8498660,clearance,"The pharmacokinetic parameters (mean +/- SD) for the studied population were elimination half-life: 101.5 +/- 26.4 min, mean residence time: 127.2 +/- 28.6 min, volume of distribution at steady state: 0.58 +/- 0.29 L/kg and clearance: 4.66 +/- 2.28 mL.kg-1 x min-1.",The pharmacokinetics of droperidol in anesthetized children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8498660/),[ml] / [kg·min],4.66,116740,DB01159,Halothane
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,53,119036,DB01159,Halothane
,12130720,total volume of distribution,"The total volume of distribution of the highly lipophilic drug thiopental was more than 60% larger than that of antipyrine, 53 versus 33 liters, respectively.",The concordance of early antipyrine and thiopental distribution kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12130720/),l,33,119037,DB01159,Halothane
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB01159,Halothane
,9366462,bioavailability,"With intramuscular administration, rocuronium's bioavailability averaged 82.6% and its absorption rate constant was 0.105 min(-1).",Bioavailability of intramuscular rocuronium in infants and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366462/),%,82.6,129967,DB01159,Halothane
,9366462,absorption rate constant,"With intramuscular administration, rocuronium's bioavailability averaged 82.6% and its absorption rate constant was 0.105 min(-1).",Bioavailability of intramuscular rocuronium in infants and children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9366462/),1/[min],0.105,129968,DB01159,Halothane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.4,135041,DB01159,Halothane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,1.3,135042,DB01159,Halothane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,16,135043,DB01159,Halothane
,7853456,half-life,"In plasma, a very short initial distribution phase in both horses and ponies, half-life 1.4 +/- 1.2 min (mean +/- SD) and 1.3 +/- 0.7 min, respectively, was obtained, which was followed by a second comparatively slower redistribution phase, half-life 16 +/- 12 min and 11 +/- 5 min, respectively.",Pharmacokinetics of thiopentone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,11,135044,DB01159,Halothane
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],1127,135045,DB01159,Halothane
,7853456,volume of distribution,"The volume of distribution for the drug was large, especially in the ponies which received isoflurane (1127 +/- 86 ml/kg), compared to the horses which received halothane (742 +/- 89 ml/kg).",Pharmacokinetics of thiopentone in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg],742,135046,DB01159,Halothane
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,147,135047,DB01159,Halothane
,7853456,elimination half-life,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),min,222,135048,DB01159,Halothane
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.5,135049,DB01159,Halothane
,7853456,clearance,"The drug had a somewhat shorter elimination half-life in the horses (147 +/- 21 min) than in than ponies (222 +/- 44 min), but no obvious difference in clearance of the drug was observed between the horses (3.5 +/- 0.5 ml/min/kg) and ponies (3.6 +/- 0.8 ml/min/kg).",Pharmacokinetics of thiopentone in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853456/),[ml] / [kg·min],3.6,135050,DB01159,Halothane
,7925209,clearance,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[ml] / [kg·min],5.2,136530,DB01159,Halothane
,7925209,terminal half-life,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),min,69,136531,DB01159,Halothane
,7925209,distribution volume at steady state,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[l] / [kg],0.22,136532,DB01159,Halothane
,7925209,Cumulative urinary excretion,Cumulative urinary excretion was around 18% within 24 h.,Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),%,18,136533,DB01159,Halothane
,2897149,Vc,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],82,139625,DB01159,Halothane
,2897149,VDSS,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg],277,139626,DB01159,Halothane
,2897149,clearance,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),[ml] / [kg·min],2.01,139627,DB01159,Halothane
,2897149,t1/2 beta,Pharmacokinetic analysis showed Vc 82 (+/- S.D. 26) ml/kg; VDSS 277 (+/- S.D. 71) ml/kg; clearance 2.01 (+/- S.D. 0.64) ml/kg/min; t1/2 beta 117 (+/- S.D. 24) min.,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),min,117,139628,DB01159,Halothane
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,5944,139629,DB01159,Halothane
,2897149,minute volume,The clinical results showed a decrease in minute volume from a mean value of 5944 ml before alfentanil to 1240 ml 1 minute after alfentanil (P less than 0.001).,The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897149/),ml,1240,139630,DB01159,Halothane
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],210,140669,DB01159,Halothane
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],129,140670,DB01159,Halothane
,2360737,Volume of distribution at steady state,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg],100,140671,DB01159,Halothane
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],7.9,140672,DB01159,Halothane
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],6.8,140673,DB01159,Halothane
,2360737,total clearance,"Volume of distribution at steady state (210 +/- 118, 129 +/- 44, and 100 +/- 22 ml/kg for infants, children, and adults, respectively) and total clearance (7.9 +/- 2.0, 6.8 +/- 1.6, and 5.3 +/- 0.9 ml.kg-1.min-1 for the three groups) decreased with increasing age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ml] / [kg·min],5.3,140674,DB01159,Halothane
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,20.0,140675,DB01159,Halothane
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,17.2,140676,DB01159,Halothane
,2360737,elimination half-life,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),min,15.7,140677,DB01159,Halothane
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],363,140678,DB01159,Halothane
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],444,140679,DB01159,Halothane
,2360737,steady state plasma concentration,"Neither elimination half-life (20.0 +/- 5.1, 17.2 +/- 5.1, and 15.7 +/- 2.5 min for the three groups) nor the steady state plasma concentration that resulted in 50% neuromuscular blockade (363 +/- 118, 444 +/- 121, and 436 +/- 122 ng/ml for the three groups) varied with age.",Pharmacokinetics and pharmacodynamics of atracurium in infants and children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2360737/),[ng] / [ml],436,140680,DB01159,Halothane
less,7224209,rate of increase in twitch tension,Twitch tension rapidly increased to a plateau (a rate of increase in twitch tension of less than 2 per cent of control per min) which was sustained in all cases.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),%,2,142422,DB01159,Halothane
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,2.9,142423,DB01159,Halothane
,7224209,time to plateau,The mean time to plateau for edrophonium was 2.9 +/- 0.21 (+/-SE) min as compared to 6.1 +/- 0.75 min for neostigmine.,Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,6.1,142424,DB01159,Halothane
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,110,142425,DB01159,Halothane
,7224209,elimination half-lives,"The elimination half-lives of edrophonium and neostigmine were 110 +/- 34 min (mean +/- SD) and 77 +/- 47 min, respectively.",Pharmacokinetics of edrophonium and neostigmine when antagonizing d-tubocurarine neuromuscular blockade in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224209/),min,77,142426,DB01159,Halothane
,6688015,EC50,Good correlation between plasma concentration and response for all patients gave an EC50 of 0.29 +/- 0.04 (SD) microgram ml-1 and a Hill coefficient of 4.6 +/- 0.5 (SD).,Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688015/),[μg] / [ml],0.29,146927,DB01159,Halothane
,6688015,Hill coefficient,Good correlation between plasma concentration and response for all patients gave an EC50 of 0.29 +/- 0.04 (SD) microgram ml-1 and a Hill coefficient of 4.6 +/- 0.5 (SD).,Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6688015/),,4.6,146928,DB01159,Halothane
,1610997,steady-state volume of distribution (Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],258,150037,DB01159,Halothane
,1610997,elimination clearance (Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],10.7,150038,DB01159,Halothane
,1610997,distribution clearance (Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],6.8,150039,DB01159,Halothane
,1610997,Vss,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg],"1,107",150040,DB01159,Halothane
,1610997,Cle,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],20.0,150041,DB01159,Halothane
,1610997,Cld,"The steady-state volume of distribution (Vss; 258 +/- 70 mL/kg), elimination clearance (Cle; 10.7 +/- 3.0 mL/kg/min), and distribution clearance (Cld; 6.8 +/- 3.3 mL/kg/min) before CPB were smaller than the Vss (1,107 +/- 373 mL/kg; P less than 0.01), Cle (20.0 +/- 3.0 mL/kg/min; P less than 0.002), and Cld (23.0 +/- 6.7 mL/kg/min; P less than 0.02) after CPB.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),[ml] / [kg·min],23.0,150042,DB01159,Halothane
,1610997,distribution half-life (t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,2.8,150043,DB01159,Halothane
,1610997,elimination half-life (t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,36,150044,DB01159,Halothane
,1610997,t1/2 lambda 1,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,1.7,150045,DB01159,Halothane
,1610997,t1/2 lambda 2,The distribution half-life (t1/2 lambda 1; 2.8 +/- 0.8 minutes) was longer and the elimination half-life (t1/2 lambda 2; 36 +/- 8 minutes) was shorter before CPB than the t1/2 lambda 1 (1.7 +/- 0.2 minutes; P less than 0.05) and t1/2 lambda 2 (68 +/- 20 minutes; P less than 0.02) after CPB.,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pigs: Part II. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610997/),min,68,150046,DB01159,Halothane
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],200,150564,DB01159,Halothane
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],400,150565,DB01159,Halothane
,2932981,steady state plasma concentrations,"These estimates were used to determine the rates of infusion that would produce steady state plasma concentrations of laudanosine of approximately 200, 400, and 800 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],800,150566,DB01159,Halothane
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],234,150567,DB01159,Halothane
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],457,150568,DB01159,Halothane
,2932981,steady state plasma concentrations,"Subsequent infusion of laudanosine in eight rabbits produced mean (+/- SD) steady state plasma concentrations of laudanosine of 234 +/- 56, 457 +/- 66, and 873 +/- 105 ng . ml-1.",Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),[ng] / [ml],873,150569,DB01159,Halothane
,2932981,MAC,The control value for MAC of halothane was 1.08 +/- 0.28%.,Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932981/),%,1,150570,DB01159,Halothane
,1976829,T1/2 alpha,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,3.9,158846,DB01159,Halothane
,1976829,T1/2 beta,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),min,102,158847,DB01159,Halothane
,1976829,V1,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],95,158848,DB01159,Halothane
,1976829,Vdss,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],264,158849,DB01159,Halothane
,1976829,Cl,"With pipecuronium, following pharmacokinetic parameters were obtained; distribution half-life; T1/2 alpha = 3.9 +/- 0.7 min (mean +/- SEM), elimination half-life; T1/2 beta = 102 +/- 12 min, volume of the central compartment; V1 = 95 +/- 13 ml.kg-1, volume of distribution at steady state; Vdss = 264 +/- 41 ml.kg-1, clearance; Cl = 1.8 +/- 0.2 ml.min-1.kg-1.","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.8,158850,DB01159,Halothane
,1976829,V1,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],38,158851,DB01159,Halothane
,1976829,Vdss,V1 and Vdss of pipecuronium were significantly larger than those of pancuronium (V1; 38 +/- 12 ml.kg-1 and Vdss; 120 +/- 4 ml.kg-1) (both P less than 0.10).,"[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg],120,158852,DB01159,Halothane
,1976829,Cl,"Reflecting the larger central volume of pipecuronium, pipecuronium tended to have a larger clearance than that of pancuroniumu (Cl; 1.1 +/- 0.2 ml.min-1.kg-1).","[Comparative pharmacokinetics of pipecuronium bromide, pancuronium bromide and vecuronium bromide in anesthetized man]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976829/),[ml] / [kg·min],1.1,158853,DB01159,Halothane
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,4.5,159420,DB01159,Halothane
,7189348,half-time,"The half-time for the fast component was 4.5 minutes, while the slow component half-time was 134.5 minutes.",Aminophylline pharmacokinetics and cardiorespiratory effects during halothane anesthesia in experimental animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189348/),min,134.5,159421,DB01159,Halothane
,8130056,PaCO2,Halothane was maintained at 1.05-1.07% end-tidal concentration with a PaCO2 of 6-7.3 kPa.,Effect of xylazine and ketamine on the pharmacokinetics of alfentanil during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130056/),kpa,6-7.3,164456,DB01159,Halothane
,8672375,onset time,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),s,72,165500,DB01159,Halothane
,8672375,time to recovery,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),s,72,165501,DB01159,Halothane
,8672375,time to recovery,"Mean onset time and time to recovery of T1 to 10% were 72 (SD 19.6) s and 27 (9.6) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,27,165502,DB01159,Halothane
,8672375,infusion rates,The infusion rates were stable in 19.8 (6.5) min.,Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,19.8,165503,DB01159,Halothane
,8672375,steady state 90% block of T1,The mean requirement for rocuronium for steady state 90% block of T1 was 528 (163.3) micrograms kg-1 h-1.,Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[μg] / [h·kg],528,165504,DB01159,Halothane
,8672375,times to attain a,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),%,90,165505,DB01159,Halothane
,8672375,T1,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),%,90,165506,DB01159,Halothane
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,0.7,165507,DB01159,Halothane
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,31,165508,DB01159,Halothane
,8672375,TOF ratio,"The times to attain a T1 of 90% and a TOF ratio of 0.7 were 31 (11.7) min and 36 (7.3) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,36,165509,DB01159,Halothane
,8672375,rate of clearance,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[ml] / [kg·min],3.3,165510,DB01159,Halothane
,8672375,mean residence time,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,67.2,165511,DB01159,Halothane
,8672375,volume of distribution at steady state,"The rate of clearance, mean residence time and volume of distribution at steady state were 3.3 (0.77) ml kg-1 min-1, 67.2 (18.8) min and 212.5 (40.1) ml kg-1, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),[ml] / [kg],212.5,165512,DB01159,Halothane
,8672375,distribution (T1/2 alpha),"The distribution (T1/2 alpha) and elimination (T1/2 beta) half-lives were 7.5 (3.33) min and 85.6 (18.4) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,7.5,165513,DB01159,Halothane
,8672375,elimination (T1/2 beta) half-lives,"The distribution (T1/2 alpha) and elimination (T1/2 beta) half-lives were 7.5 (3.33) min and 85.6 (18.4) min, respectively.",Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8672375/),min,85.6,165514,DB01159,Halothane
,6486504,ED50,The reported values for ED50 for edrophonium (obtained under similar anesthetic conditions) is 128 micrograms/kg for adults.,Clinical pharmacology of edrophonium in infants and children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[μg] / [kg],128,176742,DB01159,Halothane
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],17.8,176743,DB01159,Halothane
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],14.2,176744,DB01159,Halothane
,6486504,Total clearance,Total clearance (ml.kg-1.min-1) was greatest for infants (17.8 +/- 1.2) compared with children (14.2 +/- 7.3) and adults (8.3 +/- 2.9).,Clinical pharmacology of edrophonium in infants and children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6486504/),[ml] / [kg·min],8.3,176745,DB01159,Halothane
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],40.1,177182,DB01159,Halothane
,8346837,systemic clearance,"Except for systemic clearance of morphine during halothane and isoflurane (40.1 +/- 6.1 and 53.7 +/- 5.6 mL.min-1.kg-1, respectively), there were no differences in disposition kinetics of free morphine associated with the two inhaled anesthetics.",Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),[ml] / [kg·min],53.7,177183,DB01159,Halothane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),hg·mm,42.2,177184,DB01159,Halothane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.6,177185,DB01159,Halothane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),h·mm,46.2,177186,DB01159,Halothane
,8346837,PaCO2,Morphine increased PaCO2 to a similar degree with both halothane (from 42.2 +/- 2.1 mm Hg to 55.6 +/- 2.3 mm Hg) and isoflurane (46.2 +/- 2.4 mm Hg to 55.3 +/- 2.1 mm Hg).,Influence of inhaled anesthetics on the pharmacokinetics and pharmacodynamics of morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8346837/),mm,55.3,177187,DB01159,Halothane
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,77.72,185385,DB01159,Halothane
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],119.41,185386,DB01159,Halothane
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,52.73,185387,DB01159,Halothane
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),,178.57,185388,DB01159,Halothane
,31856324,T1/2,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),min,50.53,185389,DB01159,Halothane
,31856324,CL,"The elimination half-life (T1/2 ) of morphine was higher and the clearance rate (CL) was lower when combined with dexmedetomidine (T1/2 = 77.72 ± 20.27 min, CL = 119.41 ± 23.34 ml kg-1 min-1 ) compared to maropitant (T1/2 = 52.73 min ± 13.823 ml kg-1 min-1 , CL = 178.57 ± 70.55) or morphine alone at higher doses (T1/2 = 50.53 ± 12.55 min, CL = 187.24 ± 34.45 ml kg-1 min-1 ).",Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31856324/),[ml] / [kg·min],187.24,185390,DB01159,Halothane
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB01159,Halothane
,6239574,peak levels,There were measurable levels of laudanosine following atracurium administration with peak levels of 199 +/- 31 ng . ml-1 at 2 min.,The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6239574/),[ng] / [ml],199,187849,DB01159,Halothane
,7605420,drug clearance,2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[ml] / [kg·min],15.2,192431,DB01159,Halothane
,7605420,volume of distribution (Vss),2. Mean (+/- s.d.) values of drug clearance and volume of distribution (Vss) were 15.2 +/- 4.2 ml min-1 kg-1 and 2.1 +/- 0.8 l kg-1.,Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605420/),[l] / [kg],2.1,192432,DB01159,Halothane
,195035,Terminal half lives,Terminal half lives of d-TC of 231 and 330 minutes predicted from other studies for patients with and without renal function were consistent with plasma concentrations measured.,The pharmacokinetics of d-tubocurarine in man with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/195035/),min,231,193110,DB01159,Halothane
,195035,Terminal half lives,Terminal half lives of d-TC of 231 and 330 minutes predicted from other studies for patients with and without renal function were consistent with plasma concentrations measured.,The pharmacokinetics of d-tubocurarine in man with and without renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/195035/),min,330,193111,DB01159,Halothane
,11736682,peak plasma concentration,"The peak plasma concentration of total ropivacaine, reached within 15-241 min after the block, increased in proportion to dose, with mean values at 0.27, 0.64 and 0.90 mg/l following 1, 2 and 3 mg/kg respectively.","Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736682/),[mg] / [l],0.27,193715,DB01159,Halothane
,11736682,peak plasma concentration,"The peak plasma concentration of total ropivacaine, reached within 15-241 min after the block, increased in proportion to dose, with mean values at 0.27, 0.64 and 0.90 mg/l following 1, 2 and 3 mg/kg respectively.","Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736682/),[mg] / [l],0.64,193716,DB01159,Halothane
,11736682,peak plasma concentration,"The peak plasma concentration of total ropivacaine, reached within 15-241 min after the block, increased in proportion to dose, with mean values at 0.27, 0.64 and 0.90 mg/l following 1, 2 and 3 mg/kg respectively.","Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736682/),[mg] / [l],0.90,193717,DB01159,Halothane
,11736682,peak plasma level,"The highest individual peak plasma level of free ropivacaine was 0.070 mg/l, well below the threshold levels of CNS toxicity described in adults.","Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736682/),[mg] / [l],0.070,193718,DB01159,Halothane
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],963,193904,DB01159,Halothane
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],579,193905,DB01159,Halothane
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,78,193906,DB01159,Halothane
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,106,193907,DB01159,Halothane
,1275995,arterial tension,The mean measured arterial tension was 3.5 mm Hg.,Pharmacokinetics of halothane in the dog. Comparison of theory and measurement in individuals. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1275995/),hg·mm,3.5,194805,DB01159,Halothane
,2334622,Uptake,"Uptake of halothane was measured from the difference in the concentration in inspired and expired gas and varied from 176 to 310 mg kg-1, depending on minute ventilation.",Halothane metabolism in children. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334622/),[mg] / [kg],176,195254,DB01159,Halothane
,2334622,Uptake,"Uptake of halothane was measured from the difference in the concentration in inspired and expired gas and varied from 176 to 310 mg kg-1, depending on minute ventilation.",Halothane metabolism in children. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334622/),[mg] / [kg],310,195255,DB01159,Halothane
,2334622,urinary half-life,The urinary half-life of trifluoracetic acid was 41.8 h (range 10.4-59.1 h).,Halothane metabolism in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334622/),h,41.8,195256,DB01159,Halothane
,1829656,Onset time until maximum block,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.7,197004,DB01159,Halothane
,1829656,duration until,"Onset time until maximum block, duration until 25% recovery of twitch height, and recovery from 25 until 75% of twitch height were 1.7 (32), 53 (19) and 20 (37) min, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,53,197005,DB01159,Halothane
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,1.8,197006,DB01159,Halothane
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,19,197007,DB01159,Halothane
,1829656,Half lives,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),min,131,197008,DB01159,Halothane
,1829656,distribution volume at steady-state,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[l] / [kg],0.264,197009,DB01159,Halothane
,1829656,plasma clearance,"Half lives were 1.8 (33), 19 (34), 131 (62) min, respectively, in a three exponential decay; distribution volume at steady-state and plasma clearance were 0.264 (56) L.kg-1 and 4.0 (21) ml.kg-1.min-1, respectively.","The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[ml] / [kg·min],4.0,197010,DB01159,Halothane
,1829656,Plasma concentration at 25% recovery of the twitch height,Plasma concentration at 25% recovery of the twitch height was 1.0 mg.L-1.,"The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829656/),[mg] / [l],1.0,197011,DB01159,Halothane
,16492821,Onset time,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,2.5,197103,DB01159,Halothane
,16492821,recovery to 25% of baseline twitch height,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,37.6,197104,DB01159,Halothane
,16492821,25%-75% recovery index,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,10.9,197105,DB01159,Halothane
,16492821,Distribution,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,3.5,197106,DB01159,Halothane
,16492821,elimination half-lives,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,22.9,197107,DB01159,Halothane
,16492821,Steady-state volume of distribution,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[l] / [kg],0.207,197108,DB01159,Halothane
,16492821,total body clearance,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[ml] / [kg·min],6.8,197109,DB01159,Halothane
,16492821,rate constant,"Although the plasma-effect compartment equilibration rate constant was twofold faster (0.115 +/- 0.025 min(-1)) than that published for cisatracurium in adults, the effect compartment concentration corresponding to 50% block was similar (129 +/- 27 ng/mL).",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),1/[min],0.115,197110,DB01159,Halothane
,453592,half-life,Serum bromide half-life was 14 +/- 1.7 days.,Halothane biotransformation in anesthetists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/453592/),d,14,201638,DB01159,Halothane
,3954094,distribution half-life (t 1/2 alpha),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,3.2,201929,DB01159,Halothane
,3954094,elimination half-life (t 1/2 beta),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,58,201930,DB01159,Halothane
,3954094,volume of the central compartment (V1),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.22,201931,DB01159,Halothane
,3954094,volume of distribution (Vd area),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],1.1,201932,DB01159,Halothane
,3954094,total plasma clearance (Cl),"Using standard formulas, we derived the following data: Children: distribution half-life (t 1/2 alpha) 3.2 min, elimination half-life (t 1/2 beta) 58 min, volume of the central compartment (V1) 0.22 L/kg, volume of distribution (Vd area) 1.1 L/kg, and total plasma clearance (Cl) 11.1 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[ml] / [kg·min],11.1,201933,DB01159,Halothane
,3954094,t 1/2 alpha,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,3.6,201934,DB01159,Halothane
,3954094,t 1/2 beta,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),min,43,201935,DB01159,Halothane
,3954094,V1,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.16,201936,DB01159,Halothane
,3954094,Vd area,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[l] / [kg],0.71,201937,DB01159,Halothane
,3954094,Cl,"Adults: t 1/2 alpha 3.6 min, t 1/2 beta 43 min, V1 0.16 L/kg, Vd area 0.71 L/kg, and Cl 9.8 ml X kg-1 X min-1.",Lidocaine pharmacokinetics in children during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3954094/),[ml] / [kg·min],9.8,201938,DB01159,Halothane
,3589163,t1/2,Plasma ketamine concentrations declined biexponentially with a rapid initial distribution phase (t1/2 2.89 +/- 0.25 minutes) being followed by a slower elimination phase (t1/2 65.84 +/- 3.46 minutes).,Pharmacokinetics of intravenously administered ketamine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589163/),min,2.89,205939,DB01159,Halothane
,3589163,t1/2,Plasma ketamine concentrations declined biexponentially with a rapid initial distribution phase (t1/2 2.89 +/- 0.25 minutes) being followed by a slower elimination phase (t1/2 65.84 +/- 3.46 minutes).,Pharmacokinetics of intravenously administered ketamine in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3589163/),min,65.84,205940,DB01159,Halothane
,1558199,central blood volume,"The central blood volume averaged 23.4 ml/kg, and total blood volume averaged 78.9 ml/kg.",Minimal compartmental model of circulatory mixing of indocyanine green. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558199/),[ml] / [kg],23.4,208961,DB01159,Halothane
,1558199,total blood volume,"The central blood volume averaged 23.4 ml/kg, and total blood volume averaged 78.9 ml/kg.",Minimal compartmental model of circulatory mixing of indocyanine green. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1558199/),[ml] / [kg],78.9,208962,DB01159,Halothane
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],0.5,213228,DB01159,Halothane
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],1.0,213229,DB01159,Halothane
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],2.0,213230,DB01159,Halothane
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],4.0,213231,DB01159,Halothane
,1456524,steady-state plasma concentrations,"To obtain steady-state plasma concentrations of 0.5, 1.0, 2.0, 4.0, and 8.0 micrograms/ml, loading doses and constant infusions for ketamine were calculated for each horse on the basis of data from other studies in which the pharmacokinetic properties of ketamine were investigated.",Effects of ketamine infusion on halothane minimal alveolar concentration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1456524/),[μg] / [ml],8.0,213232,DB01159,Halothane
,1610996,Total sampling time,"Total sampling time before CPB (45 to 75 minutes) was too short to allow full characterization of the pharmacokinetics of alfentanil, but allowed estimation of the initial volume of distribution.",Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),min,45 to 75,214806,DB01159,Halothane
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214807,DB01159,Halothane
,1610996,initial,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214808,DB01159,Halothane
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],68,214809,DB01159,Halothane
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],80,214810,DB01159,Halothane
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],235,214811,DB01159,Halothane
,1610996,volume of distribution,The initial volume of distribution before CPB was smaller (68 +/- 37 mL/kg in infants and 80 +/- 32 mL/kg in children) than after CPB (235 +/- 58 mL/kg in infants and 179 +/- 99 mL/kg in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[ml] / [kg],179,214812,DB01159,Halothane
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],17.9,214813,DB01159,Halothane
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],18.3,214814,DB01159,Halothane
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],11.1,214815,DB01159,Halothane
,1610996,normalized area under the plasma concentration-time curve from 0 to 45 minutes,The normalized area under the plasma concentration-time curve from 0 to 45 minutes was larger before CPB (17.9 +/- 2.9 mg.min/L in infants and 18.3 +/- 5.4 mg.min/L in children) than after CPB (11.1 +/- 2.9 mg.min/L in infants and 12.9 +/- 3.4 mg.min/L in children; P less than 0.001).,Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: Part I. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1610996/),[mg·min] / [l],12.9,214816,DB01159,Halothane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,83,215807,DB01159,Halothane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,82,215808,DB01159,Halothane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,81,215809,DB01159,Halothane
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,77,215810,DB01159,Halothane
,2888422,heart rate,"In awake dogs, verapamil induced an increase in heart rate (24 +/- 5 bpm) and PR interval (35 +/- 9 msec) and a decrease in mean arterial pressure (-5 +/- 2 mmHg) and dP/dt (-494 +/- 116 mmHg/s).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),bpm,24,215811,DB01159,Halothane
,2979128,maximum inspired concentration,"After intubation, anesthesia was maintained with nitrous oxide-oxygen and halothane to a maximum inspired concentration of 0.6%.",Alfentanil in infants and children with congenital heart defects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),%,0.6,216495,DB01159,Halothane
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],8.2,216496,DB01159,Halothane
,2979128,total plasma clearance,"In the infants and children, total plasma clearance was 8.2 +/- 2.2 mL/kg/min and 6.3 +/- 0.8 mL/kg/min, respectively.",Alfentanil in infants and children with congenital heart defects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2979128/),[ml] / [kg·min],6.3,216497,DB01159,Halothane
,10691223,Plasma clearance,Plasma clearance was 4.77 ml x kg(-1) x min(-1) + 8.48 ml/min.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),[ml] / [kg·min],4.77,217774,DB01159,Halothane
,10691223,Plasma clearance,Plasma clearance was 4.77 ml x kg(-1) x min(-1) + 8.48 ml/min.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),[ml] / [min],8.48,217775,DB01159,Halothane
,10691223,Intramuscular bioavailability,Intramuscular bioavailability averaged 56%.,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,56,217776,DB01159,Halothane
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),1/[min],0.0491,217777,DB01159,Halothane
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,72.,217778,DB01159,Halothane
,10691223,rate constants,Absorption from the intramuscular depot had two rate constants: 0.0491 min(-1) (72.4% of absorbed drug) and 0.0110 min(-1) (27.6% of the absorbed drug).,Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),1/[min],0.0110,217779,DB01159,Halothane
,10691223,bioavailability,"After intramuscular administration, bioavailability is 56%, and plasma rapacuronium concentrations peak within 4 or 5 min.",Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691223/),%,56,217780,DB01159,Halothane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,65,221707,DB01159,Halothane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,80,221708,DB01159,Halothane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,93,221709,DB01159,Halothane
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,132,221710,DB01159,Halothane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],37,221711,DB01159,Halothane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],39,221712,DB01159,Halothane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],41,221713,DB01159,Halothane
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],64,221714,DB01159,Halothane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],2.60,221715,DB01159,Halothane
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],1.93,221716,DB01159,Halothane
,4014773,intraportal-intrinsic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],"2,110",221976,DB01159,Halothane
,4014773,intraportal-intrinsic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],799,221977,DB01159,Halothane
,4014773,systemic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],470,221978,DB01159,Halothane
,4014773,systemic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],280,221979,DB01159,Halothane
,4014773,elimination half-life,The intravenous elimination half-life was increased (P less than 0.05) from 87 +/- 12 to 155 +/- 23 min during anesthesia.,The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),min,87,221980,DB01159,Halothane
,4014773,elimination half-life,The intravenous elimination half-life was increased (P less than 0.05) from 87 +/- 12 to 155 +/- 23 min during anesthesia.,The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),min,155,221981,DB01159,Halothane
,4014773,liver plasma flow,"Although halothane anesthesia tended to lower liver plasma flow from 642 +/- 80 to 473 +/- 47 ml/min, this change was not significant.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],642,221982,DB01159,Halothane
,4014773,liver plasma flow,"Although halothane anesthesia tended to lower liver plasma flow from 642 +/- 80 to 473 +/- 47 ml/min, this change was not significant.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],473,221983,DB01159,Halothane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.15,222019,DB01159,Halothane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,1.7,222020,DB01159,Halothane
,10839928,minimum alveolar concentration,"The dogs were studied while awake and while anesthetized with 1.7%, 2.6%, and 3.5% isoflurane (1.15, 1.7, and 2.3 minimum alveolar concentration, respectively) in a randomized order determined by a Latin square experimental design.",Isoflurane alters the recirculatory pharmacokinetics of physiologic markers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839928/),,2.3,222021,DB01159,Halothane
,1282046,half-life,"Spectrophotometric analysis of rat serum showed rapid elimination of MB from the vascular system, with a half-life of 3.5 +/- 1.9 minutes.","Limitations of monastral blue as a vascular label: rapid rate of clearance is age-dependent, and interactions with anesthetics depress arterial blood pressure in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282046/),min,3.5,225221,DB01159,Halothane
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],1.4,225341,DB01159,Halothane
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],7.4,225342,DB01159,Halothane
,30078836,peak plasma concentrations,"Oseltamivir in doses of 0.3, 3 and 30 mg/kg was intravenously infused over 10 min with an interval of 20 min, which provided peak plasma concentrations 1.4, 7.4 and 125.5 µg/mL, respectively.",Electropharmacological characterization of microminipigs as a laboratory animal using anti-influenza virus drug oseltamivir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30078836/),[μg] / [ml],125.5,225343,DB01159,Halothane
,2576345,elimination half-life,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),min,215.3,225764,DB01159,Halothane
,2576345,apparent final volume of distribution,"Mean elimination half-life was 215.3 +/- 78.4 min, and the apparent final volume of distribution was 0.58 +/- 0.20 l.kg-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[l] / [kg],0.58,225765,DB01159,Halothane
,2576345,systemic clearance,"Hepatic extraction was low, as shown by a mean systemic clearance of 2.0 +/- 0.9 ml.kg-1.min-1.",[Pharmacokinetics of dextromoramide in the surgical patient]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2576345/),[ml] / [kg·min],2.0,225766,DB01159,Halothane
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.4,229332,DB01159,Halothane
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,0.45,229333,DB01159,Halothane
,7910526,ED90,"The ED90 values for Org 9453, Org 9489 and Org 9487 were 1.4, 0.45 and 1.15 mg.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),mg,1.15,229334,DB01159,Halothane
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.2,229335,DB01159,Halothane
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.6,229336,DB01159,Halothane
,7910526,onset times,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,1.5,229337,DB01159,Halothane
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.6,229338,DB01159,Halothane
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,22.0,229339,DB01159,Halothane
,7910526,durations until 25% twitch recovery,"The onset times of Org 9453 (1.5 mg.kg-1, 1.1 X ED90), Org 9489 (0.9 mg.kg-1, 2 X ED90) and Org 9487 (1.5 mg.kg-1, 1.3 X ED90) were 1.2, 1.6 and 1.5 min, and the durations until 25% twitch recovery were 8.6, 22.0 and 8.9 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,8.9,229340,DB01159,Halothane
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],6.9,229341,DB01159,Halothane
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],5.8,229342,DB01159,Halothane
,7910526,Clearances,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),[ml] / [kg·min],11.1,229343,DB01159,Halothane
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,26,229344,DB01159,Halothane
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,79,229345,DB01159,Halothane
,7910526,mean residence times,"Clearances of these doses were 6.9, 5.8, and 11.1 ml.kg-1.min-1, and mean residence times 26, 79, and 41 min, respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),min,41,229346,DB01159,Halothane
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,5,229347,DB01159,Halothane
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,11.3,229348,DB01159,Halothane
,7910526,renal excretion,"Mean renal excretion (parent compound and metabolites) within 24 hr amounted to 5, 11.3 and 12.2% respectively.","Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. ",FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7910526/),%,12.2,229349,DB01159,Halothane
,3877295,terminal half-life,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),min,286,230796,DB01159,Halothane
,3877295,clearance,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),[ml] / [min],1803,230797,DB01159,Halothane
,3877295,volume of distribution,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),l,755,230798,DB01159,Halothane
,2802213,intrinsic clearance,"The study was repeated 24 h later during 2 MAC halothane anesthesia, when the intrinsic clearance of total propranolol was decreased by 67.5 +/- 5%, from 6.14 +/- 1.1 1/min to 1.84 +/- 0.4 1/min (P less than 0.05).",Halothane inhibition of propranolol metabolism is stereoselective. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],6.14,232774,DB01159,Halothane
,2802213,intrinsic clearance,"The study was repeated 24 h later during 2 MAC halothane anesthesia, when the intrinsic clearance of total propranolol was decreased by 67.5 +/- 5%, from 6.14 +/- 1.1 1/min to 1.84 +/- 0.4 1/min (P less than 0.05).",Halothane inhibition of propranolol metabolism is stereoselective. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],1.84,232775,DB01159,Halothane
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),1/[min],10.96,232776,DB01159,Halothane
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),1/[min],2.6,232777,DB01159,Halothane
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],4.3,232778,DB01159,Halothane
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],1.5,232779,DB01159,Halothane
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],3.64,234498,DB01159,Halothane
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],25.5,234499,DB01159,Halothane
,2244445,fractional concentration of inspired oxygen (F1O2),"Groups I and II were anaesthetized with nembuthal only and the fractional concentration of inspired oxygen (F1O2) was 0.30 and 1.00, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),,0.30,236090,DB01159,Halothane
,2244445,fractional concentration of inspired oxygen (F1O2),"Groups I and II were anaesthetized with nembuthal only and the fractional concentration of inspired oxygen (F1O2) was 0.30 and 1.00, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),,1.00,236091,DB01159,Halothane
,2244445,half-life,"The mean half-life of the tracer in the lungs in Groups I-IV was 60, 58, 59 and 26 min, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),min,60,236092,DB01159,Halothane
,2244445,half-life,"The mean half-life of the tracer in the lungs in Groups I-IV was 60, 58, 59 and 26 min, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),min,58,236093,DB01159,Halothane
,2244445,half-life,"The mean half-life of the tracer in the lungs in Groups I-IV was 60, 58, 59 and 26 min, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),min,59,236094,DB01159,Halothane
,2244445,half-life,"The mean half-life of the tracer in the lungs in Groups I-IV was 60, 58, 59 and 26 min, respectively.",Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2244445/),min,26,236095,DB01159,Halothane
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],5,239161,DB01159,Halothane
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],10,239162,DB01159,Halothane
,10389810,steady-state targets,"Rats, either anesthetized with halothane or conscious and restrained, were infused to stepwise steady-state targets of 5, 10, and 20 microg/mL thiopental by computer-controlled infusions.",Enantioselectivity of thiopental distribution into the central neural tissue of rats: an interaction with halothane. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389810/),[μg] / [ml],20,239163,DB01159,Halothane
,8447208,elimination half-life,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),min,182,240009,DB01159,Halothane
,8447208,Vdss,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),l,169,240010,DB01159,Halothane
,8447208,plasma clearance,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),[ml] / [min],910,240011,DB01159,Halothane
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,61.3,246044,DB01159,Halothane
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,60,246045,DB01159,Halothane
,3729058,elimination half-life,Three-compartment modeling of plasma laudanosine concentrations yielded an elimination half-life for laudanosine of 113 +/- 24 min (mean +/- SD) and a clearance of 25 +/- 8 ml . kg-1 . min-1.,Pharmacology of laudanosine in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),min,113,250680,DB01159,Halothane
,3729058,clearance,Three-compartment modeling of plasma laudanosine concentrations yielded an elimination half-life for laudanosine of 113 +/- 24 min (mean +/- SD) and a clearance of 25 +/- 8 ml . kg-1 . min-1.,Pharmacology of laudanosine in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),[ml] / [kg·min],25,250681,DB01159,Halothane
,3729058,PaCO2,"After a 6-h sampling period, dogs were hyperventilated with halothane (FIO2 = 0.2) to a PaCO2 of 26-28 mmHg.",Pharmacology of laudanosine in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729058/),mmh,26-28,250682,DB01159,Halothane
,28654209,peak plasma concentrations,"The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 μg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs.",Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28654209/),[μg] / [ml],4.81,251153,DB01159,Halothane
,28654209,peak plasma concentrations,"The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 μg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs.",Sensitivity and Reliability of Halothane-anaesthetized Microminipigs to Assess Risk of Drug-induced Long QT Syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28654209/),[μg] / [ml],10.15,251154,DB01159,Halothane
,9915332,elimination half life,Drug activity in the tissue revealed an elimination half life of 2.3 h and negligible concentration in the blood.,Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9915332/),h,2.3,251568,DB01159,Halothane
,2265045,T1/2 alpha,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,3.1,255342,DB01159,Halothane
,2265045,T1/2 beta,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,44,255343,DB01159,Halothane
,2265045,T1/2 gamma,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,520,255344,DB01159,Halothane
,2265045,clearance,The clearance of propofol was rapid (mean 1.6 (0.24) litre min-1).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),[l] / [min],1.6,255345,DB01159,Halothane
,2265045,Vss,Propofol was distributed initially into a relatively large central compartment (mean 23.7 (6.6) litre) and was extensively redistributed (mean Vss 593 (157) litre).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),l,593,255346,DB01159,Halothane
,9041681,Km,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[mg] / [l],0.4,264909,DB01159,Halothane
,9041681,Km,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[μM] / [l],2.03,264910,DB01159,Halothane
,9041681,Vmaxc,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[kg1·mg] / [h],9.2,264911,DB01159,Halothane
,9041681,Vmaxc,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[kg1·μM] / [h],46.6,264912,DB01159,Halothane
,9041681,Vmaxc,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[mg] / [h·kg],10.2,264913,DB01159,Halothane
,9041681,Vmaxc,"The in vivo metabolic rate constants obtained were: for male rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 9.2 mg kg1 h-1 (46.6 mumol kg1 h-1); for female rats, Km = 0.4 mg litre-1 (2.03 mumol litre-1) and Vmaxc = 10.2 mg kg-1 h-1 (51.7 mumol kg-1 h-1).",Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9041681/),[μM] / [h·kg],51.7,264914,DB01159,Halothane
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],29.9,270156,DB01159,Halothane
,10598617,Plasma elimination clearance,"Plasma elimination clearance of the S-(+)-ketamine enantiomer, 29.9 ml x min(-1) x kg(-1), was higher than that of the R-(-)-enantiomer, 22.2 ml x min(-1) x kg(-1).",Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[ml] / [kg·min],22.2,270157,DB01159,Halothane
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.31,270158,DB01159,Halothane
,10598617,apparent pulmonary tissue volumes,The apparent pulmonary tissue volumes of the ketamine S-(+) and R-(-)-enantiomers (0.31 l) did not differ and was approximately twice that of antipyrine (0.16 l).,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),l,0.16,270159,DB01159,Halothane
,10598617,total volume of distribution,The peripheral tissue distribution volumes and clearances and the total volume of distribution (2.1 l/kg) were the same for both stereoisomers when elimination clearances were modeled from the rapidly equilibrating peripheral compartment.,Ketamine distribution described by a recirculatory pharmacokinetic model is not stereoselective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598617/),[l] / [kg],2.1,270160,DB01159,Halothane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.087,270709,DB01159,Halothane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.131,270710,DB01159,Halothane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.114,270711,DB01159,Halothane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.144,270712,DB01159,Halothane
,7743571,K,"The ICG clearance was less (P < 0.05) in the 2 MAC HAL-N2O group (K, 0.087 min-1) than with either awake (K, 0.131 min-1) or other groups (K, 0.114 and 0.144 min-1, in the 1 MAC HAL and ISO-N2O groups, respectively) in spite of a similar degree of the depletion of MAP in 2 MAC ISO-N2O group (K, 0.124 min-1).",Noninvasive ICG clearance test for estimating hepatic blood flow during halothane and isoflurane anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7743571/),1/[min],0.124,270713,DB01159,Halothane
,6846783,elimination half-life,"In control rats treated with olive oil and water the elimination half-life for halothane amounted to 0,78 (0,69-0.88) h (confidence limits for p = 0.95).",[Metabolism of halothane in rats with CCl4-alcohol-induced liver fibrosis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846783/),h,"0,78",271730,DB01159,Halothane
,6846783,elimination half-life,In rats with CCl4-ethanol-induced liver fibrosis and steatosis this elimination half-life was prolonged to 1.24 (1.07-1.41) h indicating an impaired metabolic degradation of halothane in these rats.,[Metabolism of halothane in rats with CCl4-alcohol-induced liver fibrosis]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6846783/),h,1.24,271731,DB01159,Halothane
